A phase II randomized study of Fragmin [dalteparin sodium] in ovarian cancer: Utility on survival (FOCUS)
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2012
At a glance
- Drugs Dalteparin sodium (Primary)
- Indications Deep vein thrombosis; Ovarian cancer; Pulmonary embolism; Thromboembolism
- Focus Biomarker; Pharmacodynamics
- Acronyms FOCUS
- 09 Feb 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
- 09 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jul 2009 Result were reported at the 22nd Congress of the International Society on Thrombosis and Haemostasis.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History